By David Templeton, Pittsburgh Post-Gazette
PITTSBURGH — With no more treatments available, the Oxford, Connecticut, man undertook the dreaded task of discussing with his wife how his demise would affect her, their 5-year-old son and 1-year-old twins.
Rounds of chemotherapy, drug treatments and a bone-marrow transplant all had failed to put Paolo Cavalli’s adult B-cell acute lymphoblastic leukemia into remission. His prognosis was poor.
“With no treatment, I was looking at that time frame” of a few months, he said.
But in a happy twist of fate, Cavalli would receive a new cancer treatment called cancer immunotherapy, which uses the immune system to fight cancer. It’s a field many researchers now are pursuing, with University of Pittsburgh immunologist Olivera Finn being one of its pioneers.
In a phase one human clinical trial, a Memorial Sloan Kettering Cancer Center team in New York City used a gene to engineer patients’ immune cells to attack B-cell leukemia. The results were dramatic. Of 16 patients suffering the final stages of B-cell leukemia, 14 went into complete remission, including Cavalli.
The study, published online Wednesday in Science Translational Medicine, says “the results strongly support the therapeutic potential” for engineered immune-cell therapy.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” stated Michel Sadelain, director of the Center for Cell Engineering at the cancer center. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Sloan Kettering’s success with the blood-based cancer raises optimism that the method could be adapted to target tumor-based cancers, including lung, pancreatic, breast and prostate.
T cells are immune cells that attack viruses, bacteria and parasites. In Sadelain’s therapy, T cells taken from the patient are engineered in the laboratory to include a gene that makes the T cell target the CD19 protein on the surface of B cells, including cancerous ones.
When the T cells are reintroduced into the patient, they target cancerous B cells, leading to remission in as few as eight days but more typically within 24 days. Sadelain said he has some understanding of why two patients didn’t respond to the treatment.
The “living cell” treatment involves T cells replicating themselves inside the body to pose a persistent threat to cancer cells, eventually leading to remission. “In the treatment, we remarkably induced complete remission with engineered T cells,” Sadelain said.
Next, Sadelain will conduct a phase two trial with more patients to confirm results, with the goal of persuading the U.S. Food and Drug Administration to forgo requirements for a phase three trial, which can be cost-prohibitive. Finn said that’s also her hope with her vaccine for colorectal and other tumor-based cancers.
Traditional therapy for the B-cell leukemia involves rounds of chemotherapy and drug treatments in pursuit of complete remission, which allows a person to undergo a bone-marrow transplant. In that procedure, the cancerous bone marrow is destroyed and replaced with healthy bone marrow from a donor.